Table 1.

Baseline characteristics of the study population (N = 552).

Characteristics
Age, years (median [IQR]) (range)	37.5 [29–50] (18–83)
Sex, male [n (%)]	337 (61.1)
BMI (kg/m2), (median [IQR]) (range)∗	24 [22–27] (15–49)
History of alcohol abuse [n (%)]†	30 (5.4)
History of intravenous drug use [n (%)]‡	10 (2.3)
Country of birth [n (%)]§
France	120 (22.1)
Europe, excluding France	59 (10.9)
North Africa	38 (7.0)
Middle East	24 (4.4)
Asia	56 (10.3)
West Indies	34 (6.3)
Pacific	1 (0.2)
Sub-Saharan Africa	210 (38.7)
Coinfections [n (%)]
HIV¶	13 (2.4)
HCV∗∗	22 (4.0)
HDV	33 (6.0)
HBeAg-negative [n (%)]	496 (90.0)
Detectable HBV DNA [n (%)]	520 (94.2)
HBV DNA level (log IU/ml), (median [IQR]) (range)	3.3 [2.4–4.4] (1.0–9.1)
HBV DNA >2,000 IU/ml [n (%)]	251 (48.5)
HBsAg level (log IU/ml), median [IQR]) (range)	3.6 [3.0–4.1] (-0.8 to 5.4)
HBV genotype [n (%)]††
A	109 (25.7)
B	22 (5.2)
C	27 (6.4)
D	147 (34.7)
E	116 (27.4)
F	1 (0.25)
G	2 (0.50)
Fibrosis stage distribution [n (%)]‡‡
F0–F1	296 (71.0)
F2	56 (13.4)
F3	26 (6.2)
F4	39 (9.4)
ALT level (U/L) (median [IQR]) (range)§§	33 [22–52] (5–4,043)
ALT >40 U/L [n (%)]	194 (37.8)
Treatment eligibility [n (%)]¶¶	151 (29.1)

^∗BMI is missing in 159 patients.

^†History of alcohol abuse is missing in 71 patients.

^‡History of intravenous drug use is missing in 109 patients.

^§Country of birth is missing in 10 patients.

^¶HIV status is missing in 20 patients.

^∗∗HCV status is missing in 7 patients.

^††HBV genotype was not determined in 129 patients owing to HBV DNA level <2.5 log IU/ml or undetectable HBV DNA.

^‡‡Fibrosis stage is missing in 135 patients.

^§§ALT level is missing in 39 patients.

^¶¶According to the 2017 EASL Clinical Practice Guidelines,¹⁰ only HBV-monoinfected patients were considered. Inconclusive findings in 23 patients.